-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QSTByNIgfcrSAISRuDBTcotGJEc9GqnbFmCIwZ5ouyXPwWYHxNGZUKTFw2wBs0cb P3nkGpvGuHzStiEZIlW6lQ== 0001144204-08-025003.txt : 20080430 0001144204-08-025003.hdr.sgml : 20080430 20080430095113 ACCESSION NUMBER: 0001144204-08-025003 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20080428 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20080430 DATE AS OF CHANGE: 20080430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Opko Health, Inc. CENTRAL INDEX KEY: 0000944809 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 752402409 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33528 FILM NUMBER: 08788111 BUSINESS ADDRESS: STREET 1: 4400 BISCAYNE BLVD. STREET 2: SUITE 900 CITY: MIAMI STATE: FL ZIP: 33137 BUSINESS PHONE: 305-575-6015 MAIL ADDRESS: STREET 1: 4400 BISCAYNE BLVD. STREET 2: SUITE 900 CITY: MIAMI STATE: FL ZIP: 33137 FORMER COMPANY: FORMER CONFORMED NAME: eXegenics Inc DATE OF NAME CHANGE: 20040505 FORMER COMPANY: FORMER CONFORMED NAME: EXEGENICS INC DATE OF NAME CHANGE: 20011114 FORMER COMPANY: FORMER CONFORMED NAME: CYTOCLONAL PHARMACEUTICS INC /DE DATE OF NAME CHANGE: 19950503 8-K 1 v112226_8-k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549 
 
FORM 8-K 

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 28, 2008

OPKO Health, Inc. 
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or other
jurisdiction of
incorporation)
 
000-26648
(Commission
File Number)
 
75-2402409
(IRS Employer
Identification No.)

4400 Biscayne Blvd
Suite 1180
Miami, Florida 33137
(Address of Principal Executive Offices)

Registrant’s telephone number, including area code: (305) 575-4138
 
____________________________________________________
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 28, 2008, the Compensation Committee of the Board of Directors (the "Compensation Committee") of OPKO Health, Inc. (the "Company") held a meeting to review certain compensation matters for its executive officers and non-executive employees. At the meeting, the Compensation Committee granted stock options to certain of the Company's executive officers to purchase the number of shares of the Company’s common stock set forth opposite their name below:

Name
Shares of Common Stock
Phillip Frost, M.D., Chief Executive Officer and Chairman
300,000
   
Jane Hsiao, Ph.D., Vice Chairman and Chief Technology Officer
250,000
   
Steven D. Rubin, Executive Vice President - Administration
200,000
   
Rao Uppaluri, Ph.D., Senior Vice President - Chief Financial Officer
175,000

Each stock option was granted effective as of April 28, 2008, with an exercise price per share equal to $1.65, the closing per share price of the Company's common stock as reported on the American Stock Exchange on April 28, 2008. The Compensation Committee determined not to increase the base salaries paid to its executive officers from the levels set in 2007. The Compensation Committee further determined that no annual cash bonus would be paid for the fiscal year ended December 31, 2007.
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
OPKO Health, Inc.
  
         
 
By:
/s/ Adam Logal
  
   
Name: 
Adam Logal
  
   
Title:
Executive Director of Finance, Chief
    Accounting Officer, Treasurer
 
Date: April 30, 2008
 


 -----END PRIVACY-ENHANCED MESSAGE-----